Serum Vitamin D Levels Affect Pathologic Complete Response in Patients Undergoing Neoadjuvant Systemic Therapy for Operable Breast Cancer
- 1 April 2018
- journal article
- research article
- Published by Elsevier in Clinical Breast Cancer
- Vol. 18 (2) , 144-149
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- The relationship between vitamin D status, physical activity and insulin resistance in overweight and obese subjectsBiomolecules and Biomedicine, 2015
- Vitamin D status at breast cancer diagnosis: correlation with tumor characteristics, disease outcome, and genetic determinants of vitamin D insufficiencyCarcinogenesis, 2012
- Pretreatment Serum Concentrations of 25-Hydroxyvitamin D and Breast Cancer Prognostic Characteristics: A Case-Control and a Case-Series StudyPLOS ONE, 2011
- Vitamin D Deficiency is Correlated with Poor Outcomes in Patients with Luminal-type Breast CancerAnnals of Surgical Oncology, 2010
- Vitamin D and breast cancer: Inhibition of estrogen synthesis and signalingThe Journal of Steroid Biochemistry and Molecular Biology, 2010
- Prognostic Effects of 25-Hydroxyvitamin D Levels in Early Breast CancerJournal of Clinical Oncology, 2009
- Intake of vitamin D and risk of breast cancer—A meta-analysisThe Journal of Steroid Biochemistry and Molecular Biology, 2008
- Inhibitory Effects of 1α,25-Dihydroxyvitamin D3 on the G1–S Phase-Controlling MachineryMolecular Endocrinology, 2001
- Calcitriol (1,25-dihydroxycholecalciferol) enhances paclitaxel antitumor activity in vitro and in vivo and accelerates paclitaxel-induced apoptosis.2001
- 1,25-Dihydroxyvitamin D3 and all-trans-retinoic acid sensitize breast cancer cells to chemotherapy-induced cell death.2000